SNOA Sonoma Pharmaceuticals, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1367083 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY38.7%
TTM net income YoY48.4%
TTM EPS YoY55.2%
Revenue 3-yr CAGR24.7%
Net income 3-yr CAGR—
Margins
Gross margin39.2%
Operating margin-3.3%
Net margin-7.6%
FCF margin-11.9%
EBITDA margin-2.8%
Returns
ROE-34.5%
ROA-11.6%
ROIC (approx.)-44.6%
Asset turnover1.52x
Leverage & solvency
Liabilities / assets61.3%
Debt / equity0.00x
Current ratio3.48x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.49x
Accruals ratio5.6%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $7.17M | $6.41M | $5.56M | $4.35M | $5.60M | $4.01M | $3.75M | $3.56M |
| Cost of revenue | $4.37M | $3.83M | $3.38M | $2.70M | $3.48M | $2.55M | $2.23M | $2.29M |
| Gross profit | $2.81M | $2.58M | $2.18M | $1.65M | $2.12M | $1.46M | $1.53M | $1.27M |
| R&D expense | $469,000 | $597,000 | $545,000 | $557,000 | $575,000 | $594,000 | $411,000 | $427,000 |
| SG&A expense | $2.05M | $2.02M | $1.99M | $1.77M | $1.88M | $1.97M | $1.77M | $1.87M |
| Operating income | $290,000 | -$40,000 | -$351,000 | -$678,000 | -$337,000 | -$1.09M | -$656,000 | -$1.03M |
| Pretax income | $382,000 | -$330,000 | -$497,000 | -$949,000 | -$731,000 | -$1.24M | -$528,000 | -$919,000 |
| Income tax | $448,000 | $0 | $84,000 | -$130,000 | -$197,000 | -$1,000 | $248,000 | $9,000 |
| Net income | -$66,000 | -$330,000 | -$581,000 | -$819,000 | -$534,000 | -$1.24M | -$776,000 | -$928,000 |
| EBITDA | $320,000 | -$8,000 | -$318,000 | -$644,000 | -$301,000 | -$1.06M | -$625,000 | -$998,000 |
| EPS (basic) | -0.01 | -0.09 | — | -0.48 | -0.32 | -0.76 | — | -0.63 |
| EPS (diluted) | -0.01 | -0.09 | — | -0.48 | -0.32 | -0.76 | — | -0.63 |
| Weighted avg. shares (diluted) | 4.91M | 3.85M | — | 1.71M | 1.65M | 1.64M | — | 1.46M |
| Balance sheet | ||||||||
| Cash & equivalents | $4.61M | $5.34M | $2.40M | $2.56M | $3.04M | $3.60M | $5.37M | $5.24M |
| Receivables | $3.58M | $3.18M | $2.53M | $2.38M | $2.70M | $2.60M | $2.23M | $2.40M |
| Inventory | $3.51M | $3.79M | $3.65M | $3.70M | $3.63M | $3.80M | $2.92M | $3.14M |
| Current assets | $15.34M | $16.27M | $12.10M | $12.14M | $12.50M | $13.11M | $12.65M | $12.38M |
| PP&E, net | $294,000 | $290,000 | $310,000 | $314,000 | $284,000 | $301,000 | $225,000 | $215,000 |
| Total assets | $17.10M | $18.11M | $13.96M | $13.62M | $13.86M | $14.59M | $13.69M | $13.67M |
| Current liabilities | $4.42M | $5.45M | $4.83M | $4.22M | $4.32M | $4.85M | $4.10M | $3.70M |
| Short-term debt | $57,000 | $140,000 | $222,000 | $0 | $56,000 | $139,000 | $220,000 | $0 |
| Total liabilities | $10.49M | $11.51M | $10.87M | $10.19M | $10.07M | $10.54M | $9.28M | $8.80M |
| Shareholders' equity | $6.61M | $6.59M | $3.10M | $3.43M | $3.79M | $4.06M | $4.41M | $4.87M |
| Shares outstanding | 5.06M | 4.79M | 1.80M | 1.73M | 1.65M | 1.64M | 1.63M | 1.62M |
| Cash flow statement | ||||||||
| Operating cash flow | -$736,000 | -$649,000 | -$519,000 | -$764,000 | -$635,000 | -$2.02M | -$95,000 | $565,000 |
| Capital expenditure | $42,000 | $2,000 | $29,000 | $47,000 | $10,000 | $106,000 | $47,000 | $2,000 |
| Free cash flow | -$778,000 | -$651,000 | -$548,000 | -$811,000 | -$645,000 | -$2.12M | -$142,000 | $563,000 |
| Investing cash flow | -$42,000 | -$2,000 | -$29,000 | -$47,000 | -$10,000 | -$106,000 | -$47,000 | -$2,000 |
| Financing cash flow | $232,000 | $3.45M | $387,000 | $210,000 | -$62,000 | -$58,000 | $242,000 | $708,000 |
| Depreciation & amortization | $30,000 | $32,000 | $33,000 | $34,000 | $36,000 | $36,000 | $31,000 | $33,000 |
| Stock-based compensation | $95,000 | $58,000 | $135,000 | $24,000 | $39,000 | $57,000 | $90,000 | $13,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.